We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Meteorite-derived Metal is a Candidate for Photodynamic Cancer Therapy
News

"Dinosaur-killing" Metal Compound Targets Nucleus of Cancer Cells

Meteorite-derived Metal is a Candidate for Photodynamic Cancer Therapy
News

"Dinosaur-killing" Metal Compound Targets Nucleus of Cancer Cells

Image credit: University of Warwick
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Meteorite-derived Metal is a Candidate for Photodynamic Cancer Therapy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A new compound based on Iridium, a rare metal which landed in the Gulf of Mexico 66 M years ago, hooks onto albumin and can attack the nucleus of cancerous cells when switched on by light.

Summary:

  • Iridium – a rare metal on earth from the meteorite that wiped out dinosaurs - attached to albumin, a protein in our blood, can penetrate into the nucleus of cancer cells and destroy them when blasted with light, researchers at the University of Warwick have found
  • It can be applied locally and in smaller doses, the next step is pre-clinical trials


“It is amazing that this large protein can penetrate into cancer cells and deliver iridium which can kill them." says Professor Peter Sadler from the Department of Chemistry at the University of Warwick
The treatment of cancer using light, called Photodynamic therapy, is based on chemical compounds called  Nuclei Overlap photosensitizers, which can be switched on by light to produce oxidising species, able to kill cancer cells. Clinicians can activate these compounds selectively where the tumour is (using optical fibres) thus killing cancer cells and leaving healthy cells intact.

Thanks to the special chemical coating they used, the Warwick group was able to hook up Iridium to the blood protein Albumin, which then glowed very brightly so they could track its passage into cancer cells, where it converted the cells’ own oxygen to a lethal form which killed them.

Not only is the newly formed molecule an excellent photosensitiser, but Albumin is able to deliver it into the nucleus inside cancer cells. The dormant compound can then be switched on by light irradiation and destroy the cancer cells from their very centre.

The bright luminescence of the iridium photosensitiser allowed its accumulation in the nucleus of tumour cells and its activation leading to the cancer cell death to be followed in real time using a microscope. Image credit: University of Warwick

Professor Peter Sadler, from the Department of Chemistry at the University of Warwick comments:

“It is amazing that this large protein can penetrate into cancer cells and deliver iridium which can kill them selectively on activation with visible light. If this technology can be translated into the clinic, it might be effective against resistant cancers and reduce the side effects of chemotherapy” -Dr Cinzia Imberti, from the University of Warwick comments:

“It is fascinating how albumin can deliver our photosensitiser so specifically to the nucleus. We are at a very early stage, but we are looking forward to see where the preclinical development of this new compound can lead.”
“Our team is not only extremely multidisciplinary, including biologists, chemists and pharmacists, but also highly international, including young researchers from China, India and Italy supported by Royal Society Newton and Sir Henry Wellcome Fellowships.”

This article has been republished from materials provided by the University of Warwick. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Zhang, P., Huang, H., Banerjee, S., Clarkson, G., Ge, C., Imberti, C., & Sadler, P. J. (2018). Nucleus‐targeted organoiridium‐albumin conjugate for photoactivated cancer therapy. Angewandte Chemie. doi:10.1002/ange.201813002

Advertisement